Redefining Possible

Music Medicine for Better Brain Health

Oscillo Biosciences is committed to improving the lives of millions of individuals affected by severe diseases and disorders of the central nervous system. Our mission is to develop innovative digital therapeutic platforms that provide hope and support to those suffering from neurodegenerative conditions, including Alzheimer’s disease.

Making Waves

Oscillo Biosciences

Oscillo Biosciences is a pre-commercial biotechnology company dedicated to developing digital therapeutic platforms that address severe neurodegenerative diseases. Our approach offers a unique perspective on some of the hardest-to-solve problems. By integrating the therapeutic potential of music with the latest advancements in neuroscience and technology, we aim to restore optimal brain function.

Retuning the Brain

Neural Oscillation Therapy for Alzheimer’s Disease

We are developing a music-based digital intervention designed to restore healthy brain function in patients with mild cognitive impairment and Alzheimer’s disease. Our approach is rooted in the understanding that brain rhythms that support memory and cognition are disrupted in individuals with Alzheimer’s disease. By stimulating brain waves at specific frequencies, we can enhance brain function, improve memory, and preserve cognitive abilities.

A Neurotechnology Ecosystem

How it Works

Our therapeutic approach combines a patient’s self-selected music with optical stimulation to create an immersive experience that engages specific brain regions. This method is effective, non-invasive, and provides people with a means of treatment that is actually enjoyable.

Self-Selected Music

serves as a highly effective carrier of rhythmic neuronal stimulation, releasing dopamine and enhancing neuroplastic pathways.

Synchronized Light Pulses

controlled by a software-based algorithm work in concert with the music to entrain brain rhythms at targeted frequencies, resulting in a therapeutic level of neuromodulation.

A Cloud-Native Technology Platform

drives an ecosystem of devices, applications and integrations, flowing real-time usage and effectiveness data to patients, caregivers and medical professionals.

Alzheimer’s Disease is a Devastating Epidemic.

More than 7 million Americans suffer from dementia due to Alzheimer’s disease, and the incidence is rising at an alarming rate.

Alzheimer’s disease and related dementias can severely affect cognition, such as learning, memory, and reasoning; interfere with activities of daily living such as bathing, walking or eating; and lead to neuropsychological dysfunctions, including anxiety, delirium, psychosis and eventual death.

Alzheimer’s disease is the 5th leading cause of death among Americans aged 65 and older.

Among the top 10 causes of death, it is the only one for which there is no known cure.

0.2

The number of Americans who are living with dementia due to Alzheimer’s disease today. By 2050, this number is projected to rise to nearly 13 million.

Increase in the number of deaths from Alzheimer’s disease between 2000 and 2019. During the same period deaths from stroke and heart disease decreased.

Health and long-term care costs for people living with dementia today. Costs are projected to reach $1 trillion by 2050.

Today, someone in the United States develops Alzheimer’s

EVERY

SECONDS

By 2050
this is projected
to be

EVERY

SECONDS

Enroll in our NIH-funded Clinical Trial!

See if you qualify